Market Scenario
Ventilator-associated
pneumonia is a type of lung infection caused to patients who are on
ventilators. Ventilator-associated pneumonia is caused mainly due to lung
disease, neurologic disease, and trauma to critically ill persons. Diagnosing VAP
requires aggressive surveillance combined with the radiographic examination,
bedside examination, and microbiologic examinations of respiratory secretions.
Growing Intensive Care Unit Admissions due to rising prevalence of respiratory
diseases, rising number of ICU beds and high incidence of traumatic injuries
provides favorable backgrounds for the market to grow. According to CDC in
2013, there were 2.8 million traumatic brain injury visits to emergency
department and hospitals. The emergency department visits of brain injury
patients increased by 47% from 2007. Thus, increasing incidence of TBI drives
the growth of the market. Furthermore, increasing geriatric population is
likely to fuel the market to grow. According
to the U.S. Census Bureau in 2015, 47.8 million people were 65 years or older,
and in 2060, 98.2 million are expected to be 65 years or older. Such increasing trend in the geriatric
population provides favorable backgrounds for the market to grow.
However, factors such as expensive diagnostic
tests, high ventilator charges, inappropriate reimbursement scenario, risks
associated with ventilators are expected to restrict the market growth during
the forecast period.
Segmentation
The global Ventilator-associated pneumonia market
is segmented on the basis of diagnosis, mode of treatment, and end-user. The
Ventilator-associated pneumonia market, by diagnosis categorized into Clinical
Examination, Radiological Examination, Microbiological Analysis and others.
Microbiological Analysis is further sub-segmented into Blood and pleural fluid
cultures, Nonquantitative or semi-quantitative airway sampling and Quantitative
cultures of airway specimens. Mode of treatment segment is segmented into
Homecare, Hospital care, and others. On the basis of end-user, the market is
segmented into Hospitals & Clinics, Research centers, Ambulatory Care Centers
and Emergency Medical Services (EMS).
On the basis of region, the global
Ventilator-associated pneumonia market is segmented into the Americas, Europe,
Asia Pacific, and the Middle East and Africa. The Americas is sub-segmented
into North America and South America. The North American region is further
segmented into the U.S. and Canada. The European region is divided into two,
namely, Western Europe and Eastern Europe. Western Europe is further classified
into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe.
The Asia Pacific region is sub-segmented into Japan, China, India, Australia,
the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and
African region is sub-segmented into the United Arab Emirates, Saudi Arabia,
Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key players
Some of the key players for the global
Ventilator-associated pneumonia market Merck & Co., Inc. (U.S.), Adenium
Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics
AG (Austria) and other.
Regional Market Summary
The Ventilator-associated pneumonia market is
dominated by North America owing to the rising geriatric population within the
region. The U.S. Census Bureau projected that in 2060, 19.7 million would be of
age 85 or older. This influences the growth of this market in this region.
It is estimated that Europe stood second in the
global Ventilator-associated pneumonia market owing to increasing prevalence of
lung diseases. According to European respiratory society, more than 50% of
deaths are due to lung diseases. Thus, increasing prevalence of lung diseases
in this region influences the growth of this market in this region.
Asia Pacific was projected to be the fastest
growing region for the global Ventilator-associated pneumonia market in 2017.
The rising geriatric population, increasing healthcare expenditure and growing
respiratory disorders in Asia is expected to drive market growth in this
region. According to The Asian Development Bank (ADB), the geriatric population
in Asia is estimated to reach 923 million by 2050. Thus, this provides
favorable backgrounds for the Ventilator-associated pneumonia market to grow.
The Middle East and Africa holds the least share in
the global Ventilator-associated pneumonia market due to the presence of
stringent government policies, poor economies, under-developed healthcare
infrastructure and low penetration of healthcare services, especially within
the African region.
Browse Complete 110 Pages Premium Research Report
Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377
Detailed
Table of Contents:
Chapter 1.
Report Prologue
Chapter 2.
Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3.
Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size
Estimation
Chapter 4.
Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic
Indicators
4.6 Technology Trends
& Assessment
Chapter 5.
Market Factor Analysis
5.1 Porter’s Five Forces
Analysis
5.1.1 Bargaining Power
Of Suppliers
5.1.2 Bargaining Power
Of Buyers
5.1.3 Threat Of New
Entrants
5.1.4 Threat Of
Substitutes
5.1.5 Intensity Of
Rivalry
...Continued
About US:
Market Research
Future (MRFR), enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact Us:
Market Research
Future
Office No. 528,
Amanora Chambers
Magarpatta Road,
Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845
9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment